Skip to main content

Advertisement

Log in

Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672–1681.

    Article  CAS  PubMed  Google Scholar 

  2. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135: 547–553.

    Article  PubMed  Google Scholar 

  3. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395–403.

    Article  CAS  PubMed  Google Scholar 

  4. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL . Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161–2171.

    Article  CAS  PubMed  Google Scholar 

  5. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889–1899.

    Article  CAS  PubMed  Google Scholar 

  6. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M . Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114: 3748–3756.

    Article  CAS  PubMed  Google Scholar 

  7. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and Thrombocytopenia. J Clin Oncol 2010; 28: 437–444.

    Article  CAS  PubMed  Google Scholar 

  8. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116: 3163–3170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154–162.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to Erwan Floch for his editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Vigouroux.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calmettes, C., Vigouroux, S., Tabrizi, R. et al. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant 46, 1587–1589 (2011). https://doi.org/10.1038/bmt.2011.179

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.179

  • Springer Nature Limited

This article is cited by

Navigation